PharmiWeb.com - Global Pharma News & Resources

Pharmaco - Press Releases

Date Title Company
18-Jun-2021 Clinerion adds aggregate patient metrics for the real-world data on Patient Network Explorer with the RWD RADAR service. Clinerion Ltd.
18-Jun-2021 SMi’s 2nd Annual Pharmaceutical Cleanroom Conference Presents must attend workshops SMi Group
18-Jun-2021 European Commission approves Aubagio® (teriflunomide) as the first oral MS therapy for first-line treatment of children and adolescents living with relapsing-remitting multiple sclerosis Sanofi
18-Jun-2021 Clinical Microbiology Market New High Growth Revenue Sources - An Update Markets and Markets
18-Jun-2021 Novartis Cosentyx® (secukinumab) recommended by NICE for adults with non-radiographic axial spondyloarthritis (nr-axSpA) Novartis
18-Jun-2021 New drug class could treat range of cancers with faulty BRCA genes The Institute of Cancer Research
18-Jun-2021 APONTIS PHARMA AG: Initial studies confirm that the share has a price potential of between 77% and 135% APONTIS PHARMA AG
18-Jun-2021 Antibacterial silver coating technology: aap's silver coated implant used for first time in patient aap Implantate AG
18-Jun-2021 Rapid Nutrition PLC: Admission to trading on the Euronext Growth Paris Market Rapid Nutrition PLC
17-Jun-2021 Euretos provides free access to its AI Platform for academic researchers to further support early disease and drug research Eurotos
17-Jun-2021 DemoDay and graduation for eight healthtech innovations from SmiLe SmiLe Incubator
17-Jun-2021 Novartis Cosentyx® (secukinumab) recommended by NICE for adults with non-radiographic axial spondyloarthritis (nr-axSpA) Novartis
17-Jun-2021 Perlara partners with Vivan Therapeutics to tackle rare genetic diseases Vivan Therapeutics
17-Jun-2021 Almirall joins BIOMAP as a new partner to advance the field of inflammatory skin conditions Almirall
17-Jun-2021 NICE RECOMMENDS LILLY’S IXEKIZUMAB (TALTZ®) FOR THE TREATMENT OF INFLAMMATORY ARTHRITIS CONDITION AXIAL SPONDYLOARTHRITIS (axSpA) Eli Lilly and Company
17-Jun-2021 Syncona Limited Final Results for the Year Ended 31 March 2021 Syncona Limited
17-Jun-2021 ONTOZRY® (cenobamate)▼ receives Marketing Authorisation in Great Britain for the treatment of focal-onset seizures in adults with uncontrolled epilepsy Angelini Pharma
17-Jun-2021 Enterome’s GeneMark-HM software highlighted as the most accurate microbiome gene prediction software in peer-reviewed publication NAR Genomics and Bioinformatics ENTEROME SA
17-Jun-2021 Neurosurgery Devices Market to Reach USD 13.5 billion by 2024 – Expanding Applications and Technological Advancement MarketsandMarkets Research Private Ltd.
17-Jun-2021 Neuromodulation Market to Reach USD 8.8 billion by 2025 – Emerging and Expanding Application MarketsandMarkets Research Private Ltd.